Positive Phase III Results Reported for Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients

Positive data have been reported from an open-label phase III randomized study of continuous lenalidomide in combination with dexamethasone in patients with newly diagnosed multiple myeloma who were not candidates for stem-cell transplant. In the FIRST trial, 1,623 patients ineligible for stem-cell transplant were randomly assigned to three treatment arms: lenalidomide plus low-dose dexamethasone in 28-day cycles until disease progression ; lenalidomide plus low-dose dexamethasone for 72 weeks ; or melphalan, prednisone, and thalidomide in 42-day cycles for 72 weeks .

http://ift.tt/1vXHqtZ